KR102036547B1 - 다중고리 유도체들, 제조 방법 그리고 그것들의 약제 용도 - Google Patents

다중고리 유도체들, 제조 방법 그리고 그것들의 약제 용도 Download PDF

Info

Publication number
KR102036547B1
KR102036547B1 KR1020147022007A KR20147022007A KR102036547B1 KR 102036547 B1 KR102036547 B1 KR 102036547B1 KR 1020147022007 A KR1020147022007 A KR 1020147022007A KR 20147022007 A KR20147022007 A KR 20147022007A KR 102036547 B1 KR102036547 B1 KR 102036547B1
Authority
KR
South Korea
Prior art keywords
formula
mmol
compound
oxy
dihydrobenzofuran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147022007A
Other languages
English (en)
Korean (ko)
Other versions
KR20140117498A (ko
Inventor
양팡롱
동큉
한지후이
왕춘페이
장링
왕양
Original Assignee
지앙수 헨그루이 메디슨 컴퍼니 리미티드
샹하이 헨그루이 파마수티컬 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지앙수 헨그루이 메디슨 컴퍼니 리미티드, 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 filed Critical 지앙수 헨그루이 메디슨 컴퍼니 리미티드
Publication of KR20140117498A publication Critical patent/KR20140117498A/ko
Application granted granted Critical
Publication of KR102036547B1 publication Critical patent/KR102036547B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020147022007A 2012-01-12 2012-12-27 다중고리 유도체들, 제조 방법 그리고 그것들의 약제 용도 Expired - Fee Related KR102036547B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210008286.9 2012-01-12
CN201210008286 2012-01-12
PCT/CN2012/087606 WO2013104257A1 (zh) 2012-01-12 2012-12-27 多环类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
KR20140117498A KR20140117498A (ko) 2014-10-07
KR102036547B1 true KR102036547B1 (ko) 2019-10-25

Family

ID=48781054

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147022007A Expired - Fee Related KR102036547B1 (ko) 2012-01-12 2012-12-27 다중고리 유도체들, 제조 방법 그리고 그것들의 약제 용도

Country Status (14)

Country Link
US (1) US9139548B2 (enExample)
EP (1) EP2803664B1 (enExample)
JP (1) JP6122871B2 (enExample)
KR (1) KR102036547B1 (enExample)
CN (1) CN103429581B (enExample)
AU (1) AU2012365706B2 (enExample)
BR (1) BR112014016648B1 (enExample)
CA (1) CA2860353A1 (enExample)
MX (1) MX357780B (enExample)
RU (1) RU2621039C1 (enExample)
TW (1) TWI588136B (enExample)
UA (1) UA115975C2 (enExample)
WO (1) WO2013104257A1 (enExample)
ZA (1) ZA201404625B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104592211B (zh) * 2013-10-31 2018-10-16 广东东阳光药业有限公司 联苯类化合物及其用途
CN104650055A (zh) * 2013-11-22 2015-05-27 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
CN104788412B (zh) * 2014-01-22 2017-02-15 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
US10968193B2 (en) 2014-08-08 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10100042B2 (en) 2014-08-08 2018-10-16 Merck Sharp & Dohme Corp. [5,6]—fused bicyclic antidiabetic compounds
EP3177282B1 (en) 2014-08-08 2021-10-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
PL3206756T3 (pl) 2014-10-14 2019-06-28 Basf Se Zastosowanie heksadeka-8,15-dienalu jako aromatycznej substancji chemicznej
CN106478616B (zh) * 2015-08-27 2020-05-12 江苏恒瑞医药股份有限公司 一种gpr40激动剂的结晶形式及其制备方法
CN108236611A (zh) * 2016-12-27 2018-07-03 江苏恒瑞医药股份有限公司 两种化合物联合在制备治疗糖尿病药物中的用途
CN108236609B (zh) * 2016-12-27 2022-10-21 江苏恒瑞医药股份有限公司 一种gpr40激动剂药物组合物及其制备方法
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
BR112020026746A2 (pt) 2018-07-13 2021-03-30 Gilead Sciences, Inc. Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição.
CN112955435B (zh) 2018-10-24 2024-09-06 吉利德科学公司 Pd-1/pd-l1抑制剂
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
PH12022552277A1 (en) 2020-02-28 2024-03-04 Kallyope Inc Gpr40 agonists
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ，インク． Ａｍｐｋアクチベーター
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
CN114163426B (zh) * 2020-09-10 2024-03-19 上海爱博医药科技有限公司 苯并含氧杂环类化合物及其医药应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258722A1 (en) * 2003-05-30 2006-11-16 Takeda Pharmaceutical Company., Ltd. Condensed ring compound
US20070244155A1 (en) 2006-03-14 2007-10-18 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
WO2008001931A2 (en) * 2006-06-27 2008-01-03 Takeda Pharmaceutical Company Limited Fused cyclic compounds
US20110313003A1 (en) 2010-06-16 2011-12-22 Metabolex, Inc. Gpr120 receptor agonists and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0772610B9 (de) * 1994-07-22 2001-07-25 Byk Gulden Lomberg Chemische Fabrik GmbH Dihydrobenzofurane
US20060257987A1 (en) 2003-08-20 2006-11-16 Gonzalez Valcarcel Isabel Cris Ppar modulators
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
JP4074616B2 (ja) * 2003-12-25 2008-04-09 武田薬品工業株式会社 ３−（４−ベンジルオキシフェニル）プロパン酸誘導体
AU2004309271A1 (en) * 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
EP1726580A4 (en) * 2004-03-15 2008-02-13 Takeda Pharmaceutical AMINOPHNYLPROPANO ACID DERIVATIVE
EP1749000A4 (en) * 2004-05-25 2009-12-30 Metabolex Inc BICYCLIC SUBSTITUTED TRIAZOLE AS PPAR MODULATORS AND METHOD FOR THE PRODUCTION THEREOF
JP2012506386A (ja) * 2008-10-21 2012-03-15 メタボレックス， インコーポレイテッド アリールｇｐｒ１２０受容体アゴニストおよびその使用
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
SG173027A1 (en) 2009-01-30 2011-08-29 Toyama Chemical Co Ltd N-acyl anthranilic acid derivative or salt thereof
BRPI1013937A2 (pt) * 2009-04-22 2016-08-09 Astellas Pharma Inc compostos de ácido carboxílico
US20120172351A1 (en) * 2009-06-09 2012-07-05 Nobuyuki Negoro Novel fused cyclic compound and use thereof
CN102153553A (zh) 2010-02-11 2011-08-17 山东轩竹医药科技有限公司 含有氨基磺酰胺基氮杂环丁烷的口服碳青霉烯化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258722A1 (en) * 2003-05-30 2006-11-16 Takeda Pharmaceutical Company., Ltd. Condensed ring compound
US20070244155A1 (en) 2006-03-14 2007-10-18 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
WO2008001931A2 (en) * 2006-06-27 2008-01-03 Takeda Pharmaceutical Company Limited Fused cyclic compounds
US20110313003A1 (en) 2010-06-16 2011-12-22 Metabolex, Inc. Gpr120 receptor agonists and uses thereof

Also Published As

Publication number Publication date
MX2014008125A (es) 2014-09-22
EP2803664B1 (en) 2018-11-21
EP2803664A1 (en) 2014-11-19
RU2621039C1 (ru) 2017-05-31
CA2860353A1 (en) 2013-07-18
BR112014016648A2 (pt) 2017-06-13
AU2012365706A1 (en) 2014-07-24
US20150005282A1 (en) 2015-01-01
CN103429581B (zh) 2015-08-26
JP2015503595A (ja) 2015-02-02
HK1188781A1 (zh) 2014-05-16
US9139548B2 (en) 2015-09-22
CN103429581A (zh) 2013-12-04
KR20140117498A (ko) 2014-10-07
MX357780B (es) 2018-07-24
TWI588136B (zh) 2017-06-21
TW201329058A (zh) 2013-07-16
AU2012365706B2 (en) 2015-08-20
JP6122871B2 (ja) 2017-04-26
WO2013104257A1 (zh) 2013-07-18
EP2803664A4 (en) 2015-10-28
UA115975C2 (uk) 2018-01-25
BR112014016648A8 (pt) 2017-07-04
ZA201404625B (en) 2015-11-25
BR112014016648B1 (pt) 2020-10-27

Similar Documents

Publication Publication Date Title
KR102036547B1 (ko) 다중고리 유도체들, 제조 방법 그리고 그것들의 약제 용도
JP7813970B2 (ja) 縮合イミダゾール誘導体、その調製方法及びその医薬的応用
ES3037650T3 (en) Heterocyclic compounds and use thereof
JP6262733B2 (ja) イミダゾリン誘導体、その製造法、およびそれらの医薬への適用
CN104507921B (zh) 苯并环丁烯类衍生物、其制备方法及其在医药上的应用
EA028946B1 (ru) Способ получения соединений для применения в качестве ингибиторов sglt2
TW202200574A (zh) Bcl-2抑制劑
WO2008069242A1 (ja) 新規２環性複素環化合物
CN105209448A (zh) 三环化合物及其用途
KR20110073580A (ko) 스핑고신-1-포스페이트 수용체 길항제
EA031105B1 (ru) Ингибиторы альдостеронсинтазы
CA2369695A1 (en) Agent for treating neuropathic pain
JP6615896B2 (ja) アルドステロン合成酵素阻害剤
KR20170090497A (ko) 디히드로피리미딘-2-온 화합물 및 그의 의약 용도
CA3129600A1 (en) 6-oxo-1,6-dihydropyridazine prodrug derivative, preparation method therefor, and application thereof in medicine
TW202115022A (zh) 吲唑類衍生物、其製備方法及其在醫藥上的應用
CA3191456A1 (en) Novel compounds having inhibitory activity on prostaglandin e2 receptor and uses thereof
HK1188781B (en) Polycyclic derivatives, preparation method and medical uses thereof
CN108239029A (zh) 一类四氢异喹啉化合物及其盐的制备和医药用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20221022

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20221022